The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted Pfizer’s marketing authorisation application for its talazoparib drug to treat metastatic breast cancer patients with an inherited BRCA mutation.

The FDA also granted priority review designation for Pfizer’s new drug application (NDA) for talazoparib.

Talazoparib is an investigational, oral, once-daily poly ADP ribose polymerase (PARP) inhibitor found to possess a dual mechanism of action in preclinical studies.

The drug was found to be potent and could block PARP enzyme activity as well as trap PARP on DNA damage sites.

Pfizer Global Product Development Oncology chief development officer Mace Rothenberg said: “Women with a hereditary BRCA mutation are typically diagnosed with breast cancer at a younger age than the overall breast cancer population and have limited treatment options when they develop advanced disease.

“Today’s filing acceptances are just the latest example of the success of Pfizer’s precision medicine approach to drug development, in this case targeting the faulty DNA damage repair process associated with BRCA mutations.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Today’s filing acceptances are just the latest example of the success of Pfizer’s precision medicine approach to drug development.”

The company’s NDA submission includes data from the randomised EMBRACA trial designed to compare talazoparib with chemotherapy in 431 women suffering from germline (inherited) BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.

Data revealed that the trial met its primary endpoint of superior progression-free survival with talazoparib that was consistent across pre-specified subgroups.

Currently, the drug is being studied for the treatment of advanced gBRCAm breast cancer, early triple negative breast cancer and DNA damage repair (DDR)-deficient prostate cancer.

It is also being investigated in conjunction with immunotherapy for different types of solid tumours.